Serious side effects associated with fluoroquinolones generally outweigh the antibiotics’ benefits for patients with uncomplicated infections like sinusitis and bronchitis, the FDA announced.
The alert comes a year after the FDA convened an advisory committee to review the risk-benefit balance for fluoroquinolones.
The committee determined that the risk wasn’t worth the potential benefit for patients with sinusitis, bronchitis, and uncomplicated urinary tract infections, for which other treatment options exist.
Fluoroquinolones, which includes ciprofloxacin (Cipro), are bactericidal agents that exhibit concentration-dependent killing against a broad spectrum of pathogens.
They also demonstrate excellent tissue penetration, with their concentrations in tissue often exceeding those in plasma.
List of Currently Available FDA-Approved
Fluoroquinolone Antibacterial Drugs for Systemic Use
The FDA previously issued safety alerts regarding systemic use of these agents in July 2008 and August 2013.
For more about these antibiotics, see: